UNIGENE LABORATORIES INC (UGNE) [Rocket]

In millions, except per share items	Mar-31-13	Dec-31-12	Jun-30-12	Mar-31-12	Dec-31-11	Sep-30-11	Jun-30-11
	10-Q	10-K	10-Q/A	10-Q/A	10-K	10-Q	10-Q
Current Assets:
Cash and cash equivalents	0.4	3.8	1.7	3.7	4.7	5.2	9.1
Accounts receivable	0.1	0.1	1.1	0.6	2.9	1.6	0.7
Inventory, net	0.7	2.9	1.2	1.4	1.3	1.7	1.9
Prepaid expenses and other current assets	0.7	0.8	1.0	0.7	0.9	0.2	0.7
Total Current Assets	1.8	13.2	5.0	7.3	10.3	9.8	13.4
Noncurrent inventory, net	0.7	1.1			1.9
Property, plant and equipment, net	1.9	2.7	2.9	3.1	3.0	3.1	2.8
Patents and other intangibles, net	1.6	1.9	2.0	2.0	2.0	2.0	2.8
Other assets	0.0	0.0	0.4	0.4	0.3	0.6	0.3
Total Assets	5.3	11.3	12.0	14.5	18.2	17.5	21.8

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable	0.5	0.7	1.0	1.3	1.5	1.2	1.2
Accrued expenses	2.1	2.2	2.0	1.6	2.1	2.1	2.0
Accrued interest	17.2		8.1	7.7	11.8	0.2	0.2

Current portion – deferred licensing revenues
Current portion – deferred gain on sale/leaseback	0.6	0.6	0.7	0.7	0.7	0.8	0.8
Current portion – capital lease obligations	0.0	0.0	0.0	0.0
Embedded conversion feature liability	16.9	28.7	15.0		12.5
Notes payable – Victory Park, net of discount of $4,030,959 and $5,894,361, respectively	43.8

Notes payable – Levys
Total Current Liabilities	96.5	104.5	84.7	54.3	5.7	7.0	6.8
Capital lease obligations, excluding current portion	0.0	0.0	0.0	0.1
Deferred licensing revenues, excluding current portion	4.8	5.1	5.6	5.8	6.1	13.2	13.2
Deferred gain on sale/leaseback, excluding current portion	0.6	0.6	0.7	0.7	0.7	0.8	0.8
Total Liabilities	101.8	110.1	91.4	83.0	83.9	78.9	76.3

Commitments and Contingencies
Stockholders’ Deficit:
Common Stock – par value $.01 per share	1.0	1.0	1.0	1.0	1.0	0.9	0.9
Additional paid-in capital	117.2	116.9	116.4	116.1	115.7	130.6	130.2
Accumulated deficit	-214.6	-216.6	-196.8	-185.5	-182.3	-193.0	-185.7
Total Stockholders’ Deficit	-96.5	-98.7	-79.4	-68.5	-65.7	-61.4	-54.5
Total Liabilities and Stockholders’ Deficit	5.3	11.3	12.0	14.5	18.2	17.5	21.8